A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism.
about
Warfarin reversalIn silico profiling of deleterious amino acid substitutions of potential pathological importance in haemophlia A and haemophlia B.Clinical utilization of the international normalized ratio (INR).Haemophilia A and haemophilia B: molecular insightsFactor IX and thrombosis.Effect of vitamin K-dependent protein precursor propeptide, vitamin K hydroquinone, and glutamate substrate binding on the structure and function of {gamma}-glutamyl carboxylaseReversal of warfarin-induced hemorrhage in the emergency department.The pharmacogenetics of coumarin therapy.Life-threatening bleeding under vitamin K antagonists in spite of an INR in the therapeutic range.Characteristics and composition of the vitamin K-dependent gamma-glutamyl carboxylase-binding domain on osteocalcin.Identification of sequences within the gamma-carboxylase that represent a novel contact site with vitamin K-dependent proteins and that are required for activity.Gene therapy for hemophilia: the clot thickens.Binding of the factor IX gamma-carboxyglutamic acid domain to the vitamin K-dependent gamma-glutamyl carboxylase active site induces an allosteric effect that may ensure processive carboxylation and regulate the release of carboxylated product.Non-fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX.Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels.Expression and characterization of the naturally occurring mutation L394R in human gamma-glutamyl carboxylase.Haemophilia A and haemophilia B: molecular insights.Increased sensitivity of factor IX to phenprocoumon as a cause of bleeding in a patient with antiphospholipid antibody associated thrombosis.
P2860
Q24672566-1F45409D-6997-4410-B09D-31154FCE7760Q30414362-155C6DE4-C5B4-4DF6-AC83-116C130C855FQ33910636-7968E90B-443E-4873-90DA-F1A8C6A12068Q33918888-A71DBC38-0CB4-4503-9F43-F0069BB0B0BBQ34104373-60B02D14-766C-45F6-B10F-D80695FE31C2Q34181436-F1B7205E-05F3-42E4-9D9E-05D4B4E2D27FQ35608280-4259BAA8-CEC9-42CA-B44A-04B2379BD52CQ36192806-6F093FD3-E07E-4201-969E-BBC8FE71F995Q37854530-E5487381-B325-4A7B-8E47-E65997E1E961Q40734569-95136E39-D3FD-412C-B036-0E7D6E6718D0Q40776115-DAB817A2-03BC-44F2-8BE4-17A8CE256473Q42184386-29E64B3D-F345-416F-A05B-4E7723AAC1B3Q44683481-5FCA1840-CD25-442D-8D97-0ACB3697ED5AQ44952808-C34738D9-3412-4E60-9520-BAA31F2793A2Q51071834-21735155-9900-4B3D-9F0A-C04E3CDDAEE5Q52581486-50A14486-E4EE-4B5F-9F68-B44D1AD98D2CQ53315892-C2EE7F9F-B6AA-4B02-954B-73DAA1098FE9Q53355868-86B41F04-7611-48AE-8011-1063648651E9
P2860
A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A mutation in the propeptide o ...... sitivity by a novel mechanism.
@en
A mutation in the propeptide o ...... sitivity by a novel mechanism.
@nl
type
label
A mutation in the propeptide o ...... sitivity by a novel mechanism.
@en
A mutation in the propeptide o ...... sitivity by a novel mechanism.
@nl
prefLabel
A mutation in the propeptide o ...... sitivity by a novel mechanism.
@en
A mutation in the propeptide o ...... sitivity by a novel mechanism.
@nl
P2093
P2860
P356
P1476
A mutation in the propeptide o ...... sitivity by a novel mechanism.
@en
P2093
P2860
P304
P356
10.1172/JCI118956
P407
P577
1996-10-01T00:00:00Z